Why Are Investors Paying Heed To These 3 Stocks - AUZ, TNG And BD1?

After the ASX wipes out almost two years of gains and touched a level of two-year low i.e. since December 2016 due to a scorching night in the US. The energy and material stocks assessed the Australian markets. Three stocks during this time gaining investor’s attention are:

AUSTRALIAN MINES LIMITED (ASX:AUZ) – The Bankable Feasibility Study demonstrated the commercial viability of constructing and operating three open pits and a 2 million ton per annum process plant at Sconi, and this proposed operation would generate average revenues from production of over half a billion dollars per year with an average annual EBITDA of around $300 million. The cash and cash equivalents increased from $4.638 million in 2017 to $8.984 million in 2018, however, due to a net loss due to the company’s position of mineral explorer no dividends were paid or declared by the company during the year. The company, by paying an exercise fee of $0.6 million exercised the option in August 2018 is set to acquire 100% interest in the Flemington Project from Jervois Mining. The stock traded at a market price of $0.050 with a daily percentage change of -18.033% as at November 21, 2018. It has undergone a performance change of 64.86% over the past 1 month.

TNG LIMITED (ASX:TNG) – TNG products experienced solid price growth over 24 months with V2O5 +900% change from US $3/lb to a peak of US $30/lb, TiO2 up by 40% from US $2,300/t to US $3,200/t and Pig Iron up by 60% from US $250/t to US $400/t. The company say that the relative weakness in the Australian dollar is also very favorable to them. The company’s IRR pre-tax was 44% in November last year. TNG has received an amount of $1.55 million as a refundable tax offset under the Federal Government’s Research and Development tax incentive scheme for eligible R&D activities undertaken during the 2017/18 financial year. With several number of leading Australian institutional investors joining the company’s share register $3.911M capital raising completed. The stock traded at a market price of $0.100 with a daily percentage change of -4.762% as at November 21, 2018. It has undergone a performance change of -4.55% over the past 1 month.

BARD1 LIFE SCIENCES LIMITED (ASX:BD1) – To take advantage of synergies in women with HBOC the company focus on commercializing BARD1-Ovarian and new BARD1-Breast cancer tests. As compared to 30 June 2017 net assets of $257,937 the net assets of the consolidated entity at 30 June 2018 totaled $1,130,487. As compared to 30 June 2017 of $726,896, total assets at 30 June 2018 totaled $1,453,137. The consolidated entity had cash and cash equivalents of $1,445,657 as at 30 June 2018 compared to 30 June 2017 of $650,051. To better position the company, the company plans to advance its diagnostic and therapeutic projects towards key development milestones and grow shareholder value in financial year 2019. For this BARD1 is exploring a range of funding and corporate options and opportunities, with a guiding principle of minimizing dilution and driving value for all shareholders. The stock traded at a market price of $0.022 with a daily percentage change of -4.348% as at November 21, 2018. It has undergone a performance change of 64.29% over the past 1 month.

These three stocks are trading near their 52-week lows and gives the investors an opportunity to get in at low levels and expect long term returns from these stocks.

Disclaimer

This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.

Â

Â